Clinical Trials Logo

Spondyloarthritis clinical trials

View clinical trials related to Spondyloarthritis.

Filter by:

NCT ID: NCT04853212 Recruiting - Spondyloarthritis Clinical Trials

The Role of Intestinal Microbiota Dysbiosis in the Development of Spondyloarthritis

RUMINOSPA
Start date: June 14, 2021
Phase: N/A
Study type: Interventional

The primary objective of this case-control study aims to explore the role of bacterium Ruminococcus gnavus (R. gnavus) with intestinal biopsy and faecal sampling in the initiation and the development of spondyloarthritis (SPA) in comparison with health control subjets (patients without chronic disease but have indication to digestive endoscopy).

NCT ID: NCT04821206 Recruiting - Clinical trials for Arthritis, Rheumatoid

PANLAR's Latin American Registry of Rheumatic Patients Treated With Jak Inhibitors

PREJAK
Start date: March 1, 2021
Phase:
Study type: Observational [Patient Registry]

This prospective, non-interventional, research registry is designed to study the comparative safety and comparative effectiveness of approved Jak Inhibitors treatment for RA-PsA-SpA in a cohort of patients and theirs controls cared for by rheumatologists across Latin América (LA).

NCT ID: NCT04806867 Completed - Clinical trials for Rheumatoid Arthritis

Selection of Patients With Chronic Inflammatory Rheumatism Requiring Management During the COVID-19 Pandemia

SePaRIC
Start date: May 1, 2020
Phase:
Study type: Observational

The project proposes to evaluate a strategy for prioritizing teleconsultation for patients with chronic inflammatory rheumatic diseases during the COVID-19 pandemia. This selection will be done through telephone contact by medical students, supervised by residents and rheumatologists on a patient database. The other objectives are to assess the impact of the pandemia on the physical and mental health of patients classified as being at risk

NCT ID: NCT04798625 Active, not recruiting - Clinical trials for Rheumatoid Arthritis

Vaccine Response to COVID-19 Vaccines in Patients Using Immunosuppressive Medication

Nor-vaC
Start date: February 15, 2021
Phase:
Study type: Observational

The purpose of this study is to assess the strength and duration of the immunological response to COVID-19 vaccines in patients treated with immunosuppressive and/or immunomodulating medication for immune-mediated inflammatory diseases in rheumatology and gastroenterology and after a liver transplantation.

NCT ID: NCT04749875 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

Study of Leukocyte Populations in Patients With Chronic Inflammatory

LIMA
Start date: March 1, 2021
Phase:
Study type: Observational

Exploration of pathophysiological mechanisms in chronic inflammatory rheumatism and rare systemic autoimmune diseases with the objective of identifying therapeutic targets.

NCT ID: NCT04700150 Completed - Spondyloarthritis Clinical Trials

Tai Chi in Spondyloarthritis

TaiChiSpA
Start date: January 7, 2019
Phase: N/A
Study type: Interventional

Our hypothesis is that tai chi sessions would increase physical activity of patients with Spondyloarthitis. The main objective is to study the effect of tai chi sessions (16 vs.0) on global physical activity of Spondyloarthitis patients, compared to a control group without tai chi.

NCT ID: NCT04673825 Completed - Psoriatic Arthritis Clinical Trials

Monitoring Spondyloarthritis With SpA-Net

TeleSpA
Start date: December 2, 2020
Phase: N/A
Study type: Interventional

Randomized controlled trial to assess the effectiveness and cost-effectiveness of an intervention combining patient initiated care and telemonitoring through the online eHealth platform SpA-Net versus standard care for patients with spondyloarthritis.

NCT ID: NCT04655612 Completed - COVID-19 Clinical Trials

Seroprevalence Study of CoV-2-SARS (COVID-19) Infection in Patients With Chronic Inflammatory Rheumatic Diseases

COVID-RIC1
Start date: December 1, 2020
Phase:
Study type: Observational

The prevalence of SARS-CoV-2 infection in chronic inflammatory rheumatic diseases has not yet been widely reported, and has been evaluated only in symptomatic patient samples. The proportion of asymptomatic or mildly symptomatic patients is unknown, in patients who share common symptoms with CoV-2-SARS infection. Our objective is to describe the prevalence of seroconversion to CoV-2-SARS by consecutive screening in routine care of patients with chronic inflammatory rheumatism with serological testing

NCT ID: NCT04602091 Recruiting - Clinical trials for Rheumatoid Arthritis

Observational Study in Patients Treated With JAK Inhibitors for Inflammatory Rheumatism (MAJIK)

MAJIK
Start date: October 8, 2019
Phase:
Study type: Observational [Patient Registry]

Janus kinase (JAK) inhibitors are a new class of molecules available to the therapeutic arsenal for chronic inflammatory rheumatic diseases.The tolerance profile of this new class needs to be better defined and its use in real life further established. The French Society of Rheumatologists intends to coordinate a prospective national registry study for this follow-up. This registry will include at least 1500 Rheumatoid Arthritis (RA) and 150 patients with psoriatic arthritis from the start of treatment with JAK inhibitor and then followed for 5 years. This registry is a longitudinal, multicentre, observational registry study. The objective of this national registry is to get a better understanding of the safety profiles of JAK inhibitors and get knowledge of their use in daily practice in order to optimize this use and potentially integrate JAK inhibitors into personalised medicine strategies. This registry will generate efficacy data, especially therapeutic maintenance, observation, allowing inter-registry comparisons with other biologic compounds in the French population, and can be aggregated with other similar registries in other countries.

NCT ID: NCT04586933 Recruiting - Clinical trials for Rheumatoid Arthritis

Nutrition in Rheumatic Diseases

EROM
Start date: December 10, 2020
Phase: N/A
Study type: Interventional

Background: Patients with inflammatory rheumatic diseases (IRD) are prone to malnutrition for several reasons. The diseases and treatment can cause reduced intake and absorption of nutrients and the inflammatory processes may cause an increased demand for nutrients, especially proteins. Studies report that nutritional status can affect disease activity. Dietary supplement of 3-4 gram omega-3 has shown beneficial effect upon disease activity in patients with IRD. Aim: To investigate whether improved dietary intake with and without supplements of omega-3 will affect disease activity in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA). Hypothesis 1: A systematic change of diet in line with the Norwegian dietary guidelines, which will result in increased intake of, among other nutrients, omega-3 fatty acids and complete protein, as well as reduced intake of saturated fat and sugar, will improve nutritional status and reduce disease activity. Hypothesis 2: A systematic change of diet (as above), included a high dose of omega-3 will further improve nutritional status and reduce disease activity compared with placebo. Design: A DB-RCT-study will be conducted. All patients will receive individualized dietary guidance by a clinical dietician for 12 weeks, before randomization to supplements of omega-3 or placebo, for 24 weeks. The supplement will be blinded for the participants, researchers and physicians. Clinical implications: The study will investigate the effect of improved diet and nutrition on treatment offered to patients with IRD to provide more evidence-based knowledge, and thus specific dietary guidelines for patients with IRD. In addition, the study might increase the understanding of the role of omega-3 in the pathogenesis of inflammation.